Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
2.200
+0.090 (4.27%)
At close: Mar 13, 2025, 4:00 PM
2.260
+0.060 (2.73%)
Pre-market: Mar 14, 2025, 8:01 AM EST
Gain Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Gain Therapeutics stock have an average target of 8.33, with a low estimate of 6.00 and a high estimate of 12. The average target predicts an increase of 278.64% from the current stock price of 2.20.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Gain Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $12 | Buy | Initiates | $12 | +445.45% | Mar 7, 2025 |
| Roth MKM | Roth MKM | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +218.18% | Dec 24, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +218.18% | Dec 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +263.64% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +263.64% | Oct 9, 2024 |
Financial Forecast
Revenue This Year
n/a
from 55.18K
Revenue Next Year
51.00K
EPS This Year
-1.00
from -1.71
EPS Next Year
-0.83
from -1.00
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 210,000 | n/a | |||
| Avg | n/a | 51,000 | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.99 | -0.60 | -1.06 | ||
| Avg | -1.00 | -0.83 | -1.23 | ||
| Low | -1.06 | -1.13 | -1.38 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.